Cargando…
Laboratory Biomarkers for Diagnosis and Prognosis in COVID-19
Severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) causes a wide spectrum of clinical manifestations, with progression to multiorgan failure in the most severe cases. Several biomarkers can be altered in coronavirus disease 2019 (COVID-19), and they can be associated with diagnosis, progno...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9091347/ https://www.ncbi.nlm.nih.gov/pubmed/35572561 http://dx.doi.org/10.3389/fimmu.2022.857573 |
_version_ | 1784704900423221248 |
---|---|
author | Battaglini, Denise Lopes-Pacheco, Miquéias Castro-Faria-Neto, Hugo C. Pelosi, Paolo Rocco, Patricia R. M. |
author_facet | Battaglini, Denise Lopes-Pacheco, Miquéias Castro-Faria-Neto, Hugo C. Pelosi, Paolo Rocco, Patricia R. M. |
author_sort | Battaglini, Denise |
collection | PubMed |
description | Severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) causes a wide spectrum of clinical manifestations, with progression to multiorgan failure in the most severe cases. Several biomarkers can be altered in coronavirus disease 2019 (COVID-19), and they can be associated with diagnosis, prognosis, and outcomes. The most used biomarkers in COVID-19 include several proinflammatory cytokines, neuron-specific enolase (NSE), lactate dehydrogenase (LDH), aspartate transaminase (AST), neutrophil count, neutrophils-to-lymphocytes ratio, troponins, creatine kinase (MB), myoglobin, D-dimer, brain natriuretic peptide (BNP), and its N-terminal pro-hormone (NT-proBNP). Some of these biomarkers can be readily used to predict disease severity, hospitalization, intensive care unit (ICU) admission, and mortality, while others, such as metabolomic and proteomic analysis, have not yet translated to clinical practice. This narrative review aims to identify laboratory biomarkers that have shown significant diagnostic and prognostic value for risk stratification in COVID-19 and discuss the possible clinical application of novel analytic strategies, like metabolomics and proteomics. Future research should focus on identifying a limited but essential number of laboratory biomarkers to easily predict prognosis and outcome in severe COVID-19. |
format | Online Article Text |
id | pubmed-9091347 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-90913472022-05-12 Laboratory Biomarkers for Diagnosis and Prognosis in COVID-19 Battaglini, Denise Lopes-Pacheco, Miquéias Castro-Faria-Neto, Hugo C. Pelosi, Paolo Rocco, Patricia R. M. Front Immunol Immunology Severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) causes a wide spectrum of clinical manifestations, with progression to multiorgan failure in the most severe cases. Several biomarkers can be altered in coronavirus disease 2019 (COVID-19), and they can be associated with diagnosis, prognosis, and outcomes. The most used biomarkers in COVID-19 include several proinflammatory cytokines, neuron-specific enolase (NSE), lactate dehydrogenase (LDH), aspartate transaminase (AST), neutrophil count, neutrophils-to-lymphocytes ratio, troponins, creatine kinase (MB), myoglobin, D-dimer, brain natriuretic peptide (BNP), and its N-terminal pro-hormone (NT-proBNP). Some of these biomarkers can be readily used to predict disease severity, hospitalization, intensive care unit (ICU) admission, and mortality, while others, such as metabolomic and proteomic analysis, have not yet translated to clinical practice. This narrative review aims to identify laboratory biomarkers that have shown significant diagnostic and prognostic value for risk stratification in COVID-19 and discuss the possible clinical application of novel analytic strategies, like metabolomics and proteomics. Future research should focus on identifying a limited but essential number of laboratory biomarkers to easily predict prognosis and outcome in severe COVID-19. Frontiers Media S.A. 2022-04-27 /pmc/articles/PMC9091347/ /pubmed/35572561 http://dx.doi.org/10.3389/fimmu.2022.857573 Text en Copyright © 2022 Battaglini, Lopes-Pacheco, Castro-Faria-Neto, Pelosi and Rocco https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Battaglini, Denise Lopes-Pacheco, Miquéias Castro-Faria-Neto, Hugo C. Pelosi, Paolo Rocco, Patricia R. M. Laboratory Biomarkers for Diagnosis and Prognosis in COVID-19 |
title | Laboratory Biomarkers for Diagnosis and Prognosis in COVID-19 |
title_full | Laboratory Biomarkers for Diagnosis and Prognosis in COVID-19 |
title_fullStr | Laboratory Biomarkers for Diagnosis and Prognosis in COVID-19 |
title_full_unstemmed | Laboratory Biomarkers for Diagnosis and Prognosis in COVID-19 |
title_short | Laboratory Biomarkers for Diagnosis and Prognosis in COVID-19 |
title_sort | laboratory biomarkers for diagnosis and prognosis in covid-19 |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9091347/ https://www.ncbi.nlm.nih.gov/pubmed/35572561 http://dx.doi.org/10.3389/fimmu.2022.857573 |
work_keys_str_mv | AT battaglinidenise laboratorybiomarkersfordiagnosisandprognosisincovid19 AT lopespachecomiqueias laboratorybiomarkersfordiagnosisandprognosisincovid19 AT castrofarianetohugoc laboratorybiomarkersfordiagnosisandprognosisincovid19 AT pelosipaolo laboratorybiomarkersfordiagnosisandprognosisincovid19 AT roccopatriciarm laboratorybiomarkersfordiagnosisandprognosisincovid19 |